SEHK:1548Life Sciences
Why Genscript Biotech (SEHK:1548) Is Up 8.0% After Legend Biotech’s CARVYKTI Drives Smaller Q3 Loss
Earlier this week, Genscript Biotech Corporation announced that its associate, Legend Biotech Corporation, reported a significant reduction in net losses for the third quarter of 2025, alongside strong sales growth for its CARVYKTI product.
This disclosure, released around Genscript’s Analyst/Investor Day, places enhanced focus on the financial ties between the two companies and the implications for Genscript’s broader business outlook.
We’ll now explore how Legend Biotech’s improved...